154 Views
Tuesday Poster Session
Category: Colon
John A. Damianos, MD
Yale University School of Medicine
New Haven, CT, United States
Antimicrobial | Subjects exposed* (N, (% of 418)) | Recurrence (%) with Concomitant ABX Exposure | Recurrence (%) without Concomitant ABX Exposure | p value |
Penicillins | 140 (33.5%) | 17/140 (12.1%) | 19/278 (6.8%) | 0.095 |
Cephalosporins | 111 (26.6%) | 15/111 (13.5%) | 21/307 (6.8%) | 0.046 |
Fluoroquinolones | 106 (25.4%) | 12/106 (11.3%) | 24/312 (7.7%) | 0.315 |
Vancomycin | 105 (25.1%) | 17/105 (16.2%) | 19/313 (6.1%) | 0.002 |
Tetracyclines | 29 (6.9%) | 5/29 (17.2%) | 31/389 (8%) | 0.092 |
Sulfonamides | 24 (5.7%) | 1/26 (4.2%) | 35/394 (8.9%) | 0.710 |
Carbapenem | 9 (2.2%) | 2/9 (22.2%) | 34/409 (8.3%) | 0.177 |
Fosfomycin | 8 (1.9%) | 2/8 (25%) | 34/410 (8.3%) | 0.145 |
Aminoglycosides | 7 (1.7%) | 2/7 (28.6%) | 34/411 (8.3%) | 0.115 |
Nitrofurantoin | 6 (1.4%) | 0/6 (0%) | 36/412 (8.7%) | 1 |
Daptomycin | 4 (1%) | 0/4 (0%) | 36/414 (8.7%) | 1 |
Macrolides | 4 (1%) | 0/4 (0%) | 36/414 (8.7%) | 1 |
Clindamycin | 3 (0.7%) | 0/3 (0%) | 36/415 (8.7%) | 1 |